Beware: things are not normal
With markets are all over the place, it is hard for investors to know what to do. But there is a strong chance that the assets that have done well over the last few years won’t do the same over the next few.
This is not a normal environment – and there is no reason to think it should be. The last decade has seen a variety of extraordinary monetary experiments and the last two years have jumped every possible shark. We’ve seen rolling economic shutdowns, a new level of quantitative easing (QE), helicopter money, insanely-low interest rates, the biggest recession ever, and of course, the biggest recovery ever.
We’ve watched vast fortunes being made in tech stocks and in cryptocurrencies – and of course, in housing. Now we have supply crunches, the (fast) return of inflation, a shift in power from capital to labour, and one hell of a pivot from behind-the-curve central banks. With all that in mind you should not be particularly surprised that markets are all over the place, or for that matter that seeing through the noise is tricky.
It is hard to know what to do. However there is one thing it is increasingly clear that you should not do – and that is to retreat to the perceived safety of the assets that have done you well over the last few years. There is a strong chance they won’t do the same over the next few. Which assets do I mean?
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
First up is US stocks and tech stocks in particular. Keeping too many of these, says Ben Inker of GMO, is likely to be the first big mistake investors make in 2022. Their outperformance in 2020 and 2021 cemented the idea that they are the lowest-risk, highest-return version of equities ever – and recent volatility aside, a safe long-term option. But their outperformance has also made the US expensive – and so remarkably unsafe. You would be better, says Inker, to cut your US exposure and move into China and emerging market equities (much cheaper).
Beware frothy valuations
Next is private equity and venture capital. Those worried about the future might see that some institutions have made fortunes here and pile in too. There are all sorts of problems with this (the difficulty of selling private assets in tricky times being an obvious one). But the key thing is price: valuations are “frothy” – too frothy to compensate for the risks. Remember too that the exit route for private equity (the bit where you get the money) is via public markets. If public markets aren’t prepared to pay as much for growth as they were (that’s why tech stocks are falling) private equity valuations obviously have to fall too. This is not a safe place to be.
Third is US bonds. When markets fell in early 2020, US Treasuries were “wonderfully protective.” But the main reason bonds outperform in bad times is because central banks can and do cut rates into the downturn. This option wasn’t available in the likes of Switzerland and Sweden in 2020. The result? Their “previously reliable defensiveness” was no longer available. That may now be the case with Treasuries. They protected you in 2020. They probably won’t in 2022.
Eagle-eyed readers will have noticed something here – the core problem with all these three things is price. A bond can only protect you if it isn’t already horribly overpriced. A very expensive growth stock can only keep making you money if investor perception of the value of that growth doesn’t change. A private equity investment can only make you money if you don’t overpay for it. You can only think that these things are safe if you think their price doesn’t matter. It usually does.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Merryn Somerset Webb started her career in Tokyo at public broadcaster NHK before becoming a Japanese equity broker at what was then Warburgs. She went on to work at SBC and UBS without moving from her desk in Kamiyacho (it was the age of mergers).
After five years in Japan she returned to work in the UK at Paribas. This soon became BNP Paribas. Again, no desk move was required. On leaving the City, Merryn helped The Week magazine with its City pages before becoming the launch editor of MoneyWeek in 2000 and taking on columns first in the Sunday Times and then in 2009 in the Financial Times
Twenty years on, MoneyWeek is the best-selling financial magazine in the UK. Merryn was its Editor in Chief until 2022. She is now a senior columnist at Bloomberg and host of the Merryn Talks Money podcast - but still writes for Moneyweek monthly.
Merryn is also is a non executive director of two investment trusts – BlackRock Throgmorton, and the Murray Income Investment Trust.
-
Higher rates are disappearing – should you fix your savings?
Fixed savings rates have dropped to their lowest levels in over a year. Should you fix your savings now ahead of a potential base rate cut in November?
By Katie Williams Published
-
Nine million people fall victim to financial scams, says Citizens Advice
The charity says that around one in five people across the UK have been caught out by a finance scam in the past year - here is how to protect your money
By Chris Newlands Published
-
What will a broken-up Google look like?
The US courts have ruled that Google is a monopoly, leaving it facing the prospect of a break-up. WIll that be a good thing?
By Matthew Lynn Published
-
How will the UK gambling sector be hit by the Budget?
There are concerns for the UK gambling sector in the lead-up to the Autumn Budget. What could be on the cards?
By Dr Matthew Partridge Published
-
HSBC returns to cost-cutting plan
HSBC is set to revamp its commercial banking division – but will it come at a cost?
By Dr Matthew Partridge Published
-
Is Brevan Howard Macro a good investment?
Holding Brevan Howard, a world-leading vehicle through an investment trust, offers diversification on the cheap
By Rupert Hargreaves Published
-
How can China boost consumption?
China's new policies may give consumption a cyclical boost, even if long-term gains require more serious reforms
By Cris Sholto Heaton Published
-
Pfizer shares rise as US investor takes $1 billion stake
Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic options appear limited
By Dr Matthew Partridge Published
-
What is the outlook for oil prices?
Oil prices will be set by the face-off between Saudi Arabia and US shale producers. Could tail risks change the possible outcome?
By Cris Sholto Heaton Published
-
A fairer deal for investment trusts
New rules on how investment trusts report costs should ditch the idea that investors only need to look at one number
By Cris Sholto Heaton Published